title: [The therapeutic effect of purified human leucocytic interferon-alpha on hemorrhagic fever with renal syndrome].
abstract: In order to know the therapeutic effect of purified human leucocytic interferon-alpha on hemorrhagic fever with renal syndrome diagnosed early (< or = 5 days). We treated 23 cases with clinical prognosis and antiviral effect significantly better than those of 21 cases in a random control group. The membrane protein (MP), nucleo protein (NP) in peripheral blood mononuclear cells (PBMC) and urine, the serum antibodies to MP and NP were determined before treatment and 2, 4, 6, 8, 10 days after the beginning of the treatment. The results showed that in the treatment group, the expressin of MP and NP in PBMC were significantly depressed. The rate of negative turning of MP and NP in PBMC was 65.22% (15/23) and 69.57% (16/23) in 10 days, while in the control group, it was 19.05% (4/21) and 14.29% (3/21). The rate of negative turning of MP and NP in urine were 78.57% (11/14) and 90.91% (10/11) and that in the control group was 30.00% (3/10) and 16.66% (1/6). There was a significant difference between the two groups (P < 0.01). The results indicated that IFN-alpha could attenuate the lesions caused directly by virus, improve patients condition and raise the cure rate through depressing the expression of the virus.
authors.affiliation: Changzhou Third People's Hospital.
authors.forename: J
authors.initials: J
authors.lastname: Bai
authors.forename: K
authors.initials: K
authors.lastname: Zhu
authors.forename: G
authors.initials: G
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D018063:Hantaan virus / Q000187:drug effects / Q000378:metabolism; D006480:Hemorrhagic Fever with Renal Syndrome / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D009687:Nuclear Proteins / Q000378:metabolism; D014763:Viral Matrix Proteins / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D009687:Nuclear Proteins; D014763:Viral Matrix Proteins